$AMED
AMEDISYS INC

2020 Q4 Form 10-Q Financial Statement

#000089626220000029 Filed on October 29, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $550.7M $544.1M $494.6M
YoY Change 9.99% 10.01% 18.52%
Cost Of Revenue $306.7M $297.7M $288.7M
YoY Change 3.76% 3.11% 15.62%
Gross Profit $244.0M $246.4M $205.9M
YoY Change 18.97% 19.67% 22.85%
Gross Profit Margin 44.31% 45.29% 41.63%
Selling, General & Admin $175.6M $179.6M $154.7M
YoY Change 12.49% 16.1% 24.26%
% of Gross Profit 71.97% 72.89% 75.13%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $8.800M $8.300M $4.300M
YoY Change 46.67% 93.02% 34.38%
% of Gross Profit 3.61% 3.37% 2.09%
Operating Expenses $184.5M $187.9M $159.1M
YoY Change 13.89% 18.1% 24.59%
Operating Profit $59.50M $63.30M $46.80M
YoY Change 38.05% 35.26% 17.29%
Interest Expense -$800.0K $2.692M $3.778M
YoY Change -55.56% -28.75% 89.75%
% of Operating Profit -1.34% 4.25% 8.07%
Other Income/Expense, Net $600.0K -$1.104M -$2.600M
YoY Change -250.0% -57.54% -275.08%
Pretax Income $62.00M $62.21M $44.24M
YoY Change 57.36% 40.6% 6.94%
Income Tax $16.50M -$10.20M $9.919M
% Of Pretax Income 26.61% -16.4% 22.42%
Net Earnings $45.10M $71.98M $34.10M
YoY Change 62.82% 111.09% 8.6%
Net Earnings / Revenue 8.19% 13.23% 6.89%
Basic Earnings Per Share $1.38 $2.20 $1.06
Diluted Earnings Per Share $1.36 $2.16 $1.03
COMMON SHARES
Basic Shares Outstanding 32.81M shares 32.66M shares 32.21M shares
Diluted Shares Outstanding 33.26M shares 33.00M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $81.80M $112.9M $20.80M
YoY Change 169.97% 442.79% 48.57%
Cash & Equivalents $81.80M $112.9M $20.76M
Short-Term Investments
Other Short-Term Assets $13.30M $30.11M $13.46M
YoY Change 62.2% 123.76% 12.63%
Inventory
Prepaid Expenses $10.22M $14.91M $10.60M
Receivables $255.1M $250.8M $254.7M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $362.0M $411.3M $299.5M
YoY Change 3.26% 37.3% 28.73%
LONG-TERM ASSETS
Property, Plant & Equipment $23.70M $24.10M $29.97M
YoY Change -15.66% -19.57% -0.81%
Goodwill $932.7M $931.5M $660.5M
YoY Change 41.64% 41.03% 103.76%
Intangibles $74.20M $84.14M $66.47M
YoY Change 14.68% 26.59% 50.01%
Long-Term Investments
YoY Change
Other Assets $33.20M $33.28M $54.26M
YoY Change -39.19% -38.67% 1.6%
Total Long-Term Assets $1.205B $1.191B $912.9M
YoY Change 32.12% 30.52% 85.08%
TOTAL ASSETS
Total Short-Term Assets $362.0M $411.3M $299.5M
Total Long-Term Assets $1.205B $1.191B $912.9M
Total Assets $1.567B $1.603B $1.212B
YoY Change 24.11% 32.2% 67.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $42.67M $39.04M $35.90M
YoY Change 36.52% 8.74% 46.42%
Accrued Expenses $166.2M $170.7M $127.1M
YoY Change 21.23% 34.33% 25.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $10.50M $10.70M $9.000M
YoY Change 6.06% 18.89% 650.0%
Total Short-Term Liabilities $456.3M $437.5M $314.7M
YoY Change 39.58% 39.04% 43.49%
LONG-TERM LIABILITIES
Long-Term Debt $204.5M $300.6M $231.6M
YoY Change -11.97% 29.79% 321.86%
Other Long-Term Liabilities $33.60M $44.39M $6.002M
YoY Change 469.49% 639.52% -4.01%
Total Long-Term Liabilities $238.1M $345.0M $237.6M
YoY Change -0.04% 45.19% 288.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $456.3M $437.5M $314.7M
Total Long-Term Liabilities $238.1M $345.0M $237.6M
Total Liabilities $756.5M $845.0M $608.9M
YoY Change 21.77% 38.77% 117.16%
SHAREHOLDERS EQUITY
Retained Earnings $430.0M $384.8M $218.7M
YoY Change 74.52% 75.94% 137.52%
Common Stock $698.3M $690.1M $634.9M
YoY Change 8.22% 8.7% 7.14%
Preferred Stock
YoY Change
Treasury Stock (at cost) $319.1M $318.8M $251.1M
YoY Change 27.01% 26.96% 4.38%
Treasury Stock Shares 4.656M shares 4.655M shares 4.353M shares
Shareholders Equity $809.2M $756.2M $602.6M
YoY Change
Total Liabilities & Shareholders Equity $1.567B $1.603B $1.212B
YoY Change 24.11% 32.2% 67.02%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income $45.10M $71.98M $34.10M
YoY Change 62.82% 111.09% 8.6%
Depreciation, Depletion And Amortization $8.800M $8.300M $4.300M
YoY Change 46.67% 93.02% 34.38%
Cash From Operating Activities $66.00M $83.00M $47.50M
YoY Change -12.23% 74.74% -30.66%
INVESTING ACTIVITIES
Capital Expenditures -$2.300M -$1.300M -$3.600M
YoY Change 43.75% -63.89% -12.2%
Acquisitions
YoY Change
Other Investing Activities $700.0K $100.0K $100.0K
YoY Change 600.0% 0.0% -103.03%
Cash From Investing Activities -$1.600M -$1.200M -$3.600M
YoY Change 23.08% -66.67% -51.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -96.50M -146.7M -37.00M
YoY Change -5178.95% 296.49% -49.32%
NET CHANGE
Cash From Operating Activities 66.00M 83.00M 47.50M
Cash From Investing Activities -1.600M -1.200M -3.600M
Cash From Financing Activities -96.50M -146.7M -37.00M
Net Change In Cash -32.10M -64.90M 6.900M
YoY Change -142.35% -1040.58% -157.98%
FREE CASH FLOW
Cash From Operating Activities $66.00M $83.00M $47.50M
Capital Expenditures -$2.300M -$1.300M -$3.600M
Free Cash Flow $68.30M $84.30M $51.10M
YoY Change -11.07% 64.97% -29.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
AMEDISYS INC
dei Entity Central Index Key
EntityCentralIndexKey
0000896262
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1454955000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
297668000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
19955000 USD
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-24260
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-3131700
dei Entity Address Address Line1
EntityAddressAddressLine1
3854 American Way
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite A
dei Entity Address City Or Town
EntityAddressCityOrTown
Baton Rouge
dei Entity Address State Or Province
EntityAddressStateOrProvince
LA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
70816
dei City Area Code
CityAreaCode
225
dei Local Phone Number
LocalPhoneNumber
292-2031
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
AMED
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32810539 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112904000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30294000 USD
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
2549000 USD
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
66196000 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
250777000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
237596000 USD
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
14906000 USD
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8243000 USD
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
30114000 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
8225000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
411250000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
350554000 USD
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
101512000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
96137000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24104000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28113000 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
94273000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
84791000 USD
CY2020Q3 us-gaap Goodwill
Goodwill
931483000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
658500000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
17165000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7044000 USD
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
84143000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
64748000 USD
CY2020Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
24189000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
21427000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33278000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
54612000 USD
CY2020Q3 us-gaap Assets
Assets
1602720000 USD
CY2019Q4 us-gaap Assets
Assets
1262745000 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
39037000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
31259000 USD
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
126543000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
120877000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
170743000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
137111000 USD
CY2020Q3 amed Provider Relief Fund Advance
ProviderReliefFundAdvance
60000000 USD
CY2019Q4 amed Provider Relief Fund Advance
ProviderReliefFundAdvance
0 USD
CY2020Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
10711000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
9927000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
30462000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
27769000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
437496000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
326943000 USD
CY2020Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
300576000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
232256000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
62519000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
56128000 USD
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
44386000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5905000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
844977000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
621232000 USD
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2019Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37457444 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36638021 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32802785 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32284051 shares
CY2020Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
37000 USD
CY2019Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
37000 USD
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
690099000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
645256000 USD
CY2020Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
4654659 shares
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
4353970 shares
CY2020Q3 us-gaap Treasury Stock Value
TreasuryStockValue
318771000 USD
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
251241000 USD
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
15000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
384840000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
246383000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
756205000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
640450000 USD
CY2020Q3 us-gaap Minority Interest
MinorityInterest
1538000 USD
CY2019Q4 us-gaap Minority Interest
MinorityInterest
1063000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
757743000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
641513000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1602720000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1262745000 USD
CY2020Q3 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
544070000 USD
CY2019Q3 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
494631000 USD
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1520814000 USD
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1454955000 USD
CY2020Q3 us-gaap Other Operating Income
OtherOperatingIncome
4812000 USD
CY2019Q3 us-gaap Other Operating Income
OtherOperatingIncome
0 USD
us-gaap Other Operating Income
OtherOperatingIncome
27592000 USD
us-gaap Other Operating Income
OtherOperatingIncome
0 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
297668000 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
288708000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
878633000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
854734000 USD
CY2020Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
123146000 USD
CY2019Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
99941000 USD
us-gaap Labor And Related Expense
LaborAndRelatedExpense
330329000 USD
us-gaap Labor And Related Expense
LaborAndRelatedExpense
293127000 USD
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
7124000 USD
CY2019Q3 us-gaap Share Based Compensation
ShareBasedCompensation
6298000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
19758000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
18451000 USD
CY2020Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
49348000 USD
CY2019Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
48474000 USD
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
142616000 USD
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
140284000 USD
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8283000 USD
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4366000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
19955000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
12440000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
485569000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
447787000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1391291000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1319036000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
63313000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
46844000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
157115000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
135919000 USD
CY2020Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
31000 USD
CY2019Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
15000 USD
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
258000 USD
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
59000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
2692000 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
3778000 USD
us-gaap Interest Expense
InterestExpense
8675000 USD
us-gaap Interest Expense
InterestExpense
11459000 USD
CY2020Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1435000 USD
CY2019Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-812000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2399000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
4120000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
122000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1975000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2318000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2404000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1104000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2600000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8336000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4876000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
62209000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
44244000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
148779000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
131043000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10202000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9919000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9175000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31105000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
72411000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
34325000 USD
us-gaap Profit Loss
ProfitLoss
139604000 USD
us-gaap Profit Loss
ProfitLoss
99938000 USD
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
430000 USD
CY2019Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
193000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1147000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
760000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
71981000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
34132000 USD
us-gaap Net Income Loss
NetIncomeLoss
138457000 USD
us-gaap Net Income Loss
NetIncomeLoss
99178000 USD
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.20
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.09
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32662000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32211000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32469000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32096000 shares
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.16
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.01
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33260000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33002000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33267000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32944000 shares
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
722259000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
914000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3123000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7124000 USD
CY2020Q3 amed Surrendered Shares
SurrenderedShares
47788000 USD
CY2020Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
300000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
72411000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
757743000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
562942000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
850000 USD
CY2019Q3 amed Stock Issued During Period Value Four Zero One K Employer Match
StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
2353000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2045000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6298000 USD
CY2019Q3 amed Surrendered Shares
SurrenderedShares
4895000 USD
CY2019Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
453000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
34325000 USD
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
603465000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
641513000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2600000 USD
amed Stock Issued During Period Value Four Zero One K Employer Match
StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
3057000 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6070000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19758000 USD
amed Surrendered Shares
SurrenderedShares
54172000 USD
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
672000 USD
amed Equity Impact Of Write Off Of Other Comprehensive Income
EquityImpactOfWriteOffOfOtherComprehensiveIncome
15000 USD
us-gaap Profit Loss
ProfitLoss
139604000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
757743000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
482633000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2384000 USD
amed Stock Issued During Period Value Four Zero One K Employer Match
StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
6966000 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3388000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18451000 USD
amed Surrendered Shares
SurrenderedShares
9385000 USD
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
910000 USD
us-gaap Profit Loss
ProfitLoss
99938000 USD
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
603465000 USD
us-gaap Profit Loss
ProfitLoss
139604000 USD
us-gaap Profit Loss
ProfitLoss
99938000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19955000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12440000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
19758000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
18451000 USD
us-gaap Pension Expense
PensionExpense
0 USD
us-gaap Pension Expense
PensionExpense
7545000 USD
amed Amortizationand Impairmentof Operating Lease Right Of Use Asset
AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
29149000 USD
amed Amortizationand Impairmentof Operating Lease Right Of Use Asset
AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
27014000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
77000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-6000 USD
us-gaap Loss On Sale Of Investments
LossOnSaleOfInvestments
2980000 USD
us-gaap Loss On Sale Of Investments
LossOnSaleOfInvestments
0 USD
amed Write Off Of Other Comprehensive Income
WriteOffOfOtherComprehensiveIncome
15000 USD
amed Write Off Of Other Comprehensive Income
WriteOffOfOtherComprehensiveIncome
0 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2762000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
17798000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2399000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
4120000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
653000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
653000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
3919000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
3727000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-6486000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
39469000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
28217000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10194000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
91000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-202000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1627000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-8145000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
25594000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
27903000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
38481000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-231000 USD
amed Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-25576000 USD
amed Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-24116000 USD
amed Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-2775000 USD
amed Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-2622000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
223040000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
126780000 USD
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
94000 USD
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
287000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
80000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
158000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2995000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6337000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
875000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
210000 USD
us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
17876000 USD
us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
0 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
299723000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
345460000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-285543000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-351562000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6070000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3388000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2600000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2384000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
54172000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
9385000 USD
amed Cash Distribution To Noncontrolling Interest
CashDistributionToNoncontrollingInterest
672000 USD
amed Cash Distribution To Noncontrolling Interest
CashDistributionToNoncontrollingInterest
910000 USD
amed Proceeds From Borrowings Under Term Loan
ProceedsFromBorrowingsUnderTermLoan
0 USD
amed Proceeds From Borrowings Under Term Loan
ProceedsFromBorrowingsUnderTermLoan
175000000 USD
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
432000000 USD
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
192500000 USD
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
357000000 USD
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
133000000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
7360000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3820000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
847000 USD
amed Funds Received From Provider Relief Fund Advance
FundsReceivedFromProviderReliefFundAdvance
60000000 USD
amed Funds Received From Provider Relief Fund Advance
FundsReceivedFromProviderReliefFundAdvance
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
81466000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
225310000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
18963000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
528000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
96490000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20229000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115453000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20757000 USD
us-gaap Interest Paid Net
InterestPaidNet
4902000 USD
us-gaap Interest Paid Net
InterestPaidNet
7756000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
30290000 USD
amed Cash Paid For Operating Lease Liabilities
CashPaidForOperatingLeaseLiabilities
26738000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
17656000 USD
amed Cash Paid For Operating Lease Liabilities
CashPaidForOperatingLeaseLiabilities
28351000 USD
amed Cash Paid For Finance Lease Liabilities
CashPaidForFinanceLeaseLiabilities
1483000 USD
amed Cash Paid For Finance Lease Liabilities
CashPaidForFinanceLeaseLiabilities
792000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
29876000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
110304000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
822000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1806000 USD
amed Lessee Operatinglease Reductionsto Ro Uassetsresultingfromreductionstoleaseobligations
LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
767000 USD
amed Lessee Operatinglease Reductionsto Ro Uassetsresultingfromreductionstoleaseobligations
LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
1235000 USD
CY2020Q3 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
39 state
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div>
CY2020Q3 amed Minimum Percent Ownership For Controlling Interest Percent
MinimumPercentOwnershipForControllingInterestPercent
0.50
CY2020Q3 amed Maximum Percent Ownership For Equity Method Percent
MaximumPercentOwnershipForEquityMethodPercent
0.50
CY2020Q3 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
14200000 USD
CY2019Q4 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
35700000 USD
amed Historical Collection Rate From Medicare
HistoricalCollectionRateFromMedicare
0.99
CY2020Q3 amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
CY2019Q3 amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Percentage Of Total Reimbursement Of Outlier Payment
PercentageOfTotalReimbursementOfOutlierPayment
0.10
amed Period Of Care As Episodic Based Revenue Duration
PeriodOfCareAsEpisodicBasedRevenueDuration
P30D
amed Episode Of Care As Episodic Based Revenue Duration
EpisodeOfCareAsEpisodicBasedRevenueDuration
P60D
CY2020Q3 amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.99
CY2019Q3 amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.99
CY2020Q3 amed Cash Balance Associated With Provider Relief Fund
CashBalanceAssociatedWithProviderReliefFund
81000000 USD
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
2500000 USD
amed Percentage Of Patient Receivables Outstanding
PercentageOfPatientReceivablesOutstanding
0.10
CY2020Q3 amed Accounts Receivable Portion Derived From Medicare
AccountsReceivablePortionDerivedFromMedicare
0.63
CY2019Q4 amed Accounts Receivable Portion Derived From Medicare
AccountsReceivablePortionDerivedFromMedicare
0.58
amed Historical Collection Rate From Medicare
HistoricalCollectionRateFromMedicare
0.99
amed Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care
RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare
0.20
amed Maximum Days To Submit Final Bill From Start Of Period Of Care
MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare
90 day
amed Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid
MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid
60 day
CY2020Q3 amed Debt Instrument Carrying Amount Excluding Finance Leases
DebtInstrumentCarryingAmountExcludingFinanceLeases
311500000 USD
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32662000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32211000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32469000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32096000 shares
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
336000 shares
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
532000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
506000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
543000 shares
CY2020Q3 amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
262000 shares
CY2019Q3 amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
259000 shares
amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
292000 shares
amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
305000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33260000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33002000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33267000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32944000 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
36000 shares
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
133000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
154000 shares
CY2020Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
314200000 USD
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
245700000 USD
CY2020Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
2900000 USD
CY2019Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
3500000 USD
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
311300000 USD
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
242200000 USD
CY2020Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
10700000 USD
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
9900000 USD
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
300600000 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
232300000 USD
CY2019Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
725000000.0 USD
CY2020Q3 amed Total Leverage Ratio
TotalLeverageRatio
1.0
CY2020Q3 amed Consolidated Interest Coverage Ratio
ConsolidatedInterestCoverageRatio
18.9
amed Health Insurance Retention Limit
HealthInsuranceRetentionLimit
1300000 USD
amed Workers Compensation Insurance Retention Limit
WorkersCompensationInsuranceRetentionLimit
1000000.0 USD
amed Professional Liability Insurance Retention Limit
ProfessionalLiabilityInsuranceRetentionLimit
300000 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 Segments
CY2020Q3 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
544100000 USD
CY2020Q3 us-gaap Other Operating Income
OtherOperatingIncome
4800000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
179700000 USD
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8300000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
485600000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
63300000 USD
CY2019Q3 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
494600000 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
288700000 USD
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
154700000 USD
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4400000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
447800000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
46800000 USD
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1520800000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
451900000 USD
us-gaap Other Operating Income
OtherOperatingIncome
27600000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
878600000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
492800000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1391300000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
157100000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
854700000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
12400000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1319000000.0 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
135900000 USD
CY2019Q1 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
100000000 USD
CY2020Q2 amed Funding Received From Cares Act
FundingReceivedFromCARESAct
100000000 USD
CY2020Q1 amed Funding Immediately Distributed To Healthcare Providers Based On Their2019 Medicare Fee For Service Reimbursements
FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
30000000000 USD
CY2020Q3 amed Increase In Estimated Future Covid19 Related Expenses
IncreaseInEstimatedFutureCOVID19RelatedExpenses
10000000 USD
CY2020Q3 amed Provider Relief Fund Advance
ProviderReliefFundAdvance
60000000 USD
CY2019Q1 us-gaap Stock Repurchase Program Expiration Date
StockRepurchaseProgramExpirationDate
2020-03-01
CY2020Q1 amed Funding For Healthcare Providers Including Hospitals
FundingForHealthcareProvidersIncludingHospitals
175000000000 USD
CY2020Q1 amed Funding Immediately Distributed To Healthcare Providers Based On Their2019 Medicare Fee For Service Reimbursements
FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
30000000000 USD
amed Estimated Future Covid19 Related Expenses
EstimatedFutureCOVID19RelatedExpenses
17000000 USD
amed Cares Act Provider Relief Funds Utilized
CARESActProviderReliefFundsUtilized
26600000 USD
CY2020Q3 amed Estimated Cares Act Provider Relief Funds Expected To Be Utilized
EstimatedCARESActProviderReliefFundsExpectedToBeUtilized
16900000 USD
CY2020Q3 amed Estimated Cares Act Provider Relief Fund Amounts To Be Repaid
EstimatedCARESActProviderReliefFundAmountsToBeRepaid
60000000.0 USD
CY2020Q3 amed Cares Act Provider Relief Funds Received By Unconsolidated Joint Ventures
CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures
1900000 USD
CY2020Q3 amed Total Cares Act Provider Relief Funds Received
TotalCARESActProviderReliefFundsReceived
105400000 USD
CY2020Q2 amed Additional Funding Distributed To Healthcare Providers
AdditionalFundingDistributedToHealthcareProviders
18000000000 USD
CY2020Q4 amed Additional Funding Distributed To Healthcare Providers
AdditionalFundingDistributedToHealthcareProviders
20000000000 USD
CY2020Q3 amed Cares Act Deferral Of Employer Share Social Security Tax
CARESActDeferralOfEmployerShareSocialSecurityTax
38500000 USD

Files In Submission

Name View Source Status
0000896262-20-000029-index-headers.html Edgar Link pending
0000896262-20-000029-index.html Edgar Link pending
0000896262-20-000029.txt Edgar Link pending
0000896262-20-000029-xbrl.zip Edgar Link pending
amed-20200930.htm Edgar Link pending
amed-20200930.xsd Edgar Link pending
amed-20200930_cal.xml Edgar Link unprocessable
amed-20200930_def.xml Edgar Link unprocessable
amed-20200930_g1.jpg Edgar Link pending
amed-20200930_htm.xml Edgar Link completed
amed-20200930_lab.xml Edgar Link unprocessable
amed-20200930_pre.xml Edgar Link unprocessable
amed-20203009xexx311.htm Edgar Link pending
amed-20203009xexx312.htm Edgar Link pending
amed-20203009xexx321.htm Edgar Link pending
amed-20203009xexx322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending